-
Abstract Number: PB0256
D Dimer levels in Children with Kawasaki Disease correlate with disease activity
-
Abstract Number: PO0008
D-dimer in SARS-CoV-2 ! its importance in diagnosis and treatment.
-
Abstract Number: PB0905
D-dimer level measured at first incident cancer-related venous thromboembolism is a predictor for recurrence: a retrospective cohort study
-
Abstract Number: VPB0120
D-Dimer Levels at Admission for Predicting In-Hospital Mortality in COVID-19 Patients
-
Abstract Number: PB1002
Daratumumab as an Adjunctive Therapy for Acquired Hemophilia A with Poor Prognostic Markers
-
Abstract Number: PB0821
Data mining for profiling the mutational landscape of von Willebrand disease
-
Abstract Number: PB0273
Dealing with pediatric cancer associated thrombosis: a monocentric retrospective cohort study
-
Abstract Number: PB0532
Deciphering the role of small sulfated molecule PTS on AT3 structure and in vitro clot formation.
-
Abstract Number: PB0375
Deciphering the TLT-1 Fibrinogen ligand interaction.
-
Abstract Number: PB1362
Decision-analysis modelling of effectiveness and cost-effectiveness of thromboprophylaxis for medical inpatients
-
Abstract Number: PB0486
Decompensated cirrhosis with bacterial infections shows a peculiar derangement of the hemostatic balance
-
Abstract Number: OC 57.4
Decreased DNase activity in severe COVID-19 correlates with increased circulating NET burden
-
Abstract Number: PB0026
Decreased Levels of Factor VIII During Acute Ischemic Stroke Predict Excellent Outcome Thirty Days After
-
Abstract Number: PB1310
Decreased mitochondrial DNA copy number in patients with history of recurrent venous thromboembolism
-
Abstract Number: OC 63.1
Decreased thrombin generation profile is associated with severe bleeding phenotype in hemophilia: data from the Hemophilia in the Netherlands study
-
Abstract Number: OC 69.2
Deep learning of structural variations: genomic and bioinformatic lessons from antithrombin deficiency.
-
Abstract Number: OC 53.2
Deep mutational scan of the VWF C domains to define mutations associated with VWD
-
Abstract Number: OC 42.2
Deep Vein Thrombosis and Pulmonary Embolism Rates in Total Hip and Total Knee Arthroplasty Patients-A Claims Database Study
-
Abstract Number: PO0066
Deep vein thrombosis of the forearm after fracture immobilization
-
Abstract Number: VPB0283
Deep venous thrombosis in a child with Down syndrome as a presenting manifestation of acute lymphoblastic leukemia
-
Abstract Number: VPB0364
Defective megakaryopoiesis in ETV6-variant carriers results from an aberrant megakaryocyte-erythroid progenitor population
-
Abstract Number: PB1261
Delayed CCL26 trafficking in the secretory pathway of STX5 depleted Endothelial Cells
-
Abstract Number: PB0006
Delayed Diagnosis of Acquired Hemophilia A Results in Worse Clinical Outcome
-
Abstract Number: VPB0902
Deletion of TGF-β1 on platelets attenuates pulmonary arterial hypertension by enhancing aerobic glycolysis of pulmonary arterial smooth muscle cell
-
Abstract Number: PB0664
Demographic and Baseline Clinical Characteristics of Patients With Hemophilia A in China: Real-world Data From the AHEAD International Study
-
Abstract Number: PB0598
Demonstration of Prothrombotic Status in patients with COVID-19 using Thromboelastography and a Novel T-TAS assay
-
Abstract Number: VPB1389
Descriptive analysis of venous thromboembolic disease in patients under contraceptive treatment in sector III of Aragón
-
Abstract Number: PB1156
Desmopressin in hemophilia A carriers: determinants and duration of FVIII response
-
Abstract Number: PB0868
Detection of hyperfunctioning platelets and novel phenotypic platelet subtypes
-
Abstract Number: PB0177
Detection of IgG4 anti-FVIII levels as complementary test to define the ITI outcome in patients with hemophilia A: results from the BrazIT Study
-
Abstract Number: OC 33.4
Detection of platelet-activating antibodies associated with VITT by flow cytometry: an italian experience
-
Abstract Number: PB1146
Determinants of successful immune tolerance induction in persons with hemophilia A – systematic review and meta-analysis
-
Abstract Number: PB0622
Determining the dominant-negative causality of FXIII heterozygous mutations using a bi-cistronic, bi-tagged expression system
-
Abstract Number: OC 54.4
Development and validation of a clinical prediction model for 90-day venous thromboembolism risk following total hip and total knee arthroplasty
-
Abstract Number: VPB0472
Development of a consensus-based cross-domain protocol for the management of elastic compression stocking therapy: a modified Delphi study
-
Abstract Number: PB0147
Development of a microfluidic model to evaluate extracorporeal circuit material thrombogenicity
-
Abstract Number: PB0729
Development of a viral vector for hemopexin protein expression for gene therapy in disorders associated with increased levels of free extracellular heme
-
Abstract Number: PB0867
Development of an endothelialized in vitro thrombosis model with a disease relevant extracellular matrix
-
Abstract Number: VPB0233
Development of clinical pharmacist led Anticoagulation stewardship program in cardiac care setting in developing country.
-
Abstract Number: PB1244
Development of Consensus on Standardized Nomenclature for PT-VWD- Joint Project from the ISTH SSCs on Platelet Physiology, VWF and Genomics in thrombosis and Haemostasis
-
Abstract Number: PB0805
Development of Personalized CRISPR/Cas9 Based Gene Correction Therapy for Von Willebrand Disease
-
Abstract Number: OC 29.4
Development of recombinant antibodies targeting the coagulation factor XIII-B subunit for research and therapeutic use
-
Abstract Number: PB0235
Diagnosis, predisposing factors, and Management of Disseminated Intravascular Coagulation in neonatal Intensive care Unit in a tertiary Care Hospital
-
Abstract Number: OC 31.4
Diagnostic accuracy of V/Q and Q SPECT/CT in patients with suspected pulmonary embolism: a systematic review and meta-analysis
-
Abstract Number: PB0974
Diagnostic efficacy of ECG-derived ventricular gradient for the detection of chronic thromboembolic pulmonary hypertension in patients with acute pulmonary embolism
-
Abstract Number: VPB0839
Diagnostic Errors Of Von Willebrand Disease In A Developing Country: Analysis Of 38 Years Data
-
Abstract Number: PB1093
Diagnostic Potential of Rapid Automated ADAMTS13 Inhibitor Screening and Quantification
-
Abstract Number: VPB0138
Diagnostic strategies for pulmonary embolism in patients hospitalized for COVID-19: role of clinical prediction rules
-
Abstract Number: VPB1117
Diagnostic Value Of Tromboelastography Using Korean Society On Thrombosis And Haemostasis Criteria On Disseminated Intravascular Coagulation Induced Sepsis Patients
-
Abstract Number: VPB1020
Dielectric blood coagulometry for evaluation of coagulation activity of blood samples spiked with direct oral anticoagulant.
-
Abstract Number: OC 50.4
Differences in bleeding profiles and venous clot structures between emicizumab and factor VIII-treated mice
-
Abstract Number: PB1316
Differences in coagulation parameters associated with glucocorticoid treatment in patients with a first venous thrombosis: data from the MEGA study
-
Abstract Number: OC 38.3
Different contribution of monocyte- and platelet-derived microvesicles to endothelial behavior
-
Abstract Number: VPB0365
Differential Autoregulation of RUNX1 by Isoforms RUNX1 B and RUNX1 C in Megakaryocytic Cells
-
Abstract Number: PB0601
Differential expression of platelet microRNAs in hospitalized patients with severe COVID-19
-
Abstract Number: OC 09.3
Differential fate of Von Willebrand factor and Von Willebrand factor propeptide following release from platelet alpha-granules
-
Abstract Number: PB0550
Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa
-
Abstract Number: PB1308
Differential proteomic profile of patients with Pulmonary Embolism (PE) related to events during follow-up: chronic thromboembolic pulmonary hypertension (CTEPH) or occult cancer.
-
Abstract Number: PB0508
Differential quantitative proteomics reveals potential molecular mechanisms responsible for platelet hyperactivity and increased thrombotic risk in diabetes mellitus patients.
-
Abstract Number: PB0406
Differential regulation of GPVI-stimulated Y/S phosphorylation of Syk and Btk by both PKC and PKA in human platelets
-
Abstract Number: PB1068
Dilute Thrombin Time versus activated Partial thromboplastin Time to monitor Argatroban in critically ill patients.
-
Abstract Number: PB0748
Diminished platelet CLEC-2 sensitivity in kaposiform hemangioendothelioma identified with novel CLEC-2 antagonists
-
Abstract Number: PB0984
Direct comparison of Andexanet alfa and prothrombin complex concentrates in the reversal of direct factor Xa inhibitors – An in vitro study
-
Abstract Number: OC 17.5
Direct Oral Anti-Coagulant (DOAC) external quality assessment (EQA) scheme assay results and interpretations from UKNEQAS BC DOAC Survey 19 2021.
-
Abstract Number: OC 62.5
Direct oral anticoagulant prescribing in patients with a very low bodyweight – experience from King’s College Hospital
-
Abstract Number: OC 51.1
Direct oral anticoagulants cause placental vascular abnormalities and epigenetic reprogramming in placenta and the offspring
-
Abstract Number: PB0443
Direct Oral Anticoagulants compared with Warfarin for the Treatment of Left Ventricular Thrombosis post Myocardial Infarction
-
Abstract Number: OC 48.3
Direct Oral Anticoagulants for the Treatment of Splanchnic Vein Thrombosis: A Systematic Review and Meta-Analysis
-
Abstract Number: PB0928
Direct Oral Anticoagulants for Treatment of Venous Thromboembolism in Patients with Hematological Malignancies
-
Abstract Number: PB0449
Direct oral anticoagulants in the management of cerebral sinus vein thrombosis: A single centre experience
-
Abstract Number: PB1255
Disclosing the role of endothelial dysfunction in the pathogenesis of unprovoked venous thromboembolism by using patient-specific endothelial colony-forming cells
-
Abstract Number: PB1208
Discontinuation of thrombopoietin receptor agonists: a 10 year real-world experience from an academic hospital in Madrid
-
Abstract Number: PB1075
Discrepant results for ADAMTS13 assays with different activity assays. Artefact or cause for concern?
-
Abstract Number: PB0877
Discriminating platelet subpopulations on the expression level of HLA-I highlights the high reactivity of young versus old platelets
-
Abstract Number: PB1066
Discrimination between acquired hemophilia A and lupus anticoagulant using global coagulation assays
-
Abstract Number: OC 04.4
Disease Relapse in immune Thrombotic Thrombocytopenic Purpura and treatment with Anti-CD20 Monoclonal Antibodies – 10-years’ experience from the UK TTP Registry
-
Abstract Number: VPB0518
Disentangle the relationship between depression and arterial thrombosis associated with BDNFVal66Met polymorphism: the role of α 2-adrenergic receptor pathway
-
Abstract Number: PB0775
Disruption of the interaction of platelets with leukocytes by a novel short synthetic peptide targeting P-selectin
-
Abstract Number: PO0046
Distribution of Inherited Thrombophilia Disorder and Experiences of Extremely Low Level of Protein-C: A Single-Center Study
-
Abstract Number: PB0191
DNA extracellular traps as potential biomarker of chronic haemophilic synovitis and therapeutic perspective in patients treated with PRP
-
Abstract Number: VPB0647
DNase 1 unveils the presence and unlocks the thrombolytic potential of intraveneously administered t-PA in large vessel occlusion acute ischemic stroke
-
Abstract Number: PB1197
Do Regulatory T cells Reemerge with Resolution of Childhood Immune Thrombocytopenia?
-
Abstract Number: PO0060
DOACs CHALLENGING CHOICE IN CONCOMITANT JUGULAR VEIN AND HEPATIC ARTERY THROMBOSIS IN A BREAST CANCER PATIENT WITH LIVER ARTERIAL INFUSION CHEMOTHERAPY (LAIC): A UNIQUE CLINICAL CASE.
-
Abstract Number: OC 43.5
Domain-specific nanobodies distinguish intact and proteolyzed forms of von Willebrand factor in congenital von Willebrand disease
-
Abstract Number: VPB0690
Dose optimisation in children with severe haemophilia A on long-term octanate® prophylaxis
-
Abstract Number: PB0193
Dose optimization for prophylaxis using a pharmacokinetic model for factor IX products in severe hemophilia B
-
Abstract Number: PB1184
Dose-effect analyses of FEIBA in low volume plasma samples of inhibitor patients using a newly defined chemiluminescent-based TGA
-
Abstract Number: OC 57.5
Downregulation of Thrombomodulin-Thrombin-Activated Protein C pathway as a mechanism for SARS-CoV-2 induced endotheliopathy and microvascular thrombosis
-
Abstract Number: PB0410
DRVVT in APLA- As a single test and in combination with Anti B2-Glycoprotein and Anti Cardiolipin.
-
Abstract Number: PB0786
Dual anti-platelet therapy-associated bleeding is exacerbated by platelet counts < 100 x 10^9/L in mice due to impaired initial hemostatic plug formation
-
Abstract Number: PB0509
Dual Antiplatelet Therapy Is Associated With High α-Tubulin Acetylation in Platelets From Coronary Artery Disease Patients
-
Abstract Number: OC 11.4
Dynamic changes in activated protein C during major haemorrhage protocol and associated fibrinolytic response
-
Abstract Number: VPB0127
DYNAMICS OF HEMOSTASIS SYSTEM’S PARAMETERS IN PATIENTS WITH SEVERE COURSE OF COVID-19 UNDERGOING EXTRACORPOREAL MEMBRANE OXYGENATION
-
Abstract Number: PB0482
Dysfunctional Hemostasis in Patients under Extracorporeal Life Support. A Rapid Diagnostic Approach with Therapeutical Guidance Intentions
-
Abstract Number: OC 29.5
Dysregulated fibrinogen γ-chain cross-linking in FibγΔ5 mice drives acute liver injury after acetaminophen overdose
ISTH 2022 Congress
July 9-13, 2022. London, England, UK.